Omni surgical system reduces IOP, glaucoma medications at 6 months
Patients with glaucoma treated with the Omni surgical system in the GEMINI study experienced a statistically significant reduction in both IOP and IOP-lowering medications.
The Omni surgical system (Sight Sciences) is a manually operated device for delivery of small amounts of viscoelastic fluid during ophthalmic surgery. It is also indicated for cutting trabecular meshwork tissue during trabeculotomy. Surgeons can use the system to target all three sources of resistance in the conventional outflow pathway, which are the trabecular meshwork, Schlemm’s canal and collector channels, according to a company press release.
The GEMINI study included 150 patients with mild to moderate open-angle glaucoma who were on one to four glaucoma medications. Interim results of the first 76 patients to complete 6 months of the study showed a 75% reduction in IOP-lowering medications, and 56 patients did not require medications at 6 months after treatment. The medication-free patients experienced an average IOP reduction of 40% compared with their unmedicated baseline IOP. Additionally, 95% of the medication-free patients experienced a greater than 20% reduction in IOP with an IOP range of 6 mm Hg to 18 mm Hg.
No incidences of recurring hyphema or loss of visual acuity were reported. No patients required secondary glaucoma surgery. Adverse events were mild and required no additional treatment.
Twelve-month outcomes are expected to be reported in the first half of 2021.
Read more about